EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
History
EQRx was founded in 2020 by a group of passionate innovators and scientists with backgrounds in Chemistry, Biochemistry, and Medicine. We are headquartered in San Francisco, with offices in Berlin and London.
Mission
We’re facing one of the biggest healthcare challenges of our time: Every day, people are diagnosed with life-changing conditions, but can’t afford the medicines they need. And that’s just accepted as the status quo.
lWE BELIEVE THERE’S A BETTER WAY.
So, we decided it was time for a change.
At EQRx, we’re trailblazing a revolution.
To make medicines more affordable for people who need them
To bring back trust between the pharma industry and patients
To make drug pricing transparent
Vision
EQRx will build a better healthcare system where the names of people and communities come first, and everyone has access to the medicines they need at a price they can afford.
